CAR T Cell Therapy
City of Hope has one of the most comprehensive CAR T cell programs in the world, with nearly 50 CAR T cell clinical trials ongoing or opening soon, treating both hematologic malignancies and solid tumors. Some of these trials will be combined with other immune therapies to further improve efficacy.
AT THE FOREFRONT OF CAR T CELL THERAPY
• Over 630 patients treated in nearly 80 CAR T cell trials (current or completed), targeting both solid tumors and hematologic malignancies
• One of the first to offer the earliest FDA-approved therapies, axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) - Brexucabtagene autoleucel (Tecartus) is also available for patients at City of Hope
• Onsite CAR T cell engineering and manufacturing in our GMP facilities
• Pioneering CAR T cell therapy as a bridge to transplant for patients with leukemia and lymphoma...
More Info Less Info